Capital Management Corp VA Sells 29,654 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Capital Management Corp VA lessened its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 8.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 322,912 shares of the company’s stock after selling 29,654 shares during the period. Harmony Biosciences accounts for approximately 1.4% of Capital Management Corp VA’s investment portfolio, making the stock its 28th largest holding. Capital Management Corp VA owned about 0.56% of Harmony Biosciences worth $8,899,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. American Century Companies Inc. boosted its stake in Harmony Biosciences by 16.5% in the second quarter. American Century Companies Inc. now owns 1,501,420 shares of the company’s stock valued at $47,445,000 after acquiring an additional 212,633 shares in the last quarter. LSV Asset Management lifted its holdings in shares of Harmony Biosciences by 24.6% during the 2nd quarter. LSV Asset Management now owns 1,488,502 shares of the company’s stock valued at $47,037,000 after purchasing an additional 293,541 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Harmony Biosciences by 36.3% during the 2nd quarter. Marshall Wace LLP now owns 1,209,484 shares of the company’s stock valued at $38,220,000 after purchasing an additional 321,947 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Harmony Biosciences by 9.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,054,348 shares of the company’s stock worth $33,321,000 after purchasing an additional 88,598 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in Harmony Biosciences by 127.6% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 906,909 shares of the company’s stock worth $28,658,000 after buying an additional 508,498 shares during the last quarter. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Insider Transactions at Harmony Biosciences

In other Harmony Biosciences news, CEO Jeffrey M. Dayno sold 25,933 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $37.15, for a total transaction of $139,163.90. Following the transaction, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at approximately $910,955.15. This trade represents a 13.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 50,640 shares of company stock worth $1,932,256 in the last 90 days. Company insiders own 23.60% of the company’s stock.

Harmony Biosciences Stock Down 0.9%

NASDAQ:HRMY opened at $36.52 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 3.75 and a quick ratio of 3.72. The company’s fifty day moving average price is $37.41 and its 200-day moving average price is $34.26. Harmony Biosciences Holdings, Inc. has a 1-year low of $25.52 and a 1-year high of $40.87. The firm has a market capitalization of $2.10 billion, a P/E ratio of 11.48, a PEG ratio of 0.34 and a beta of 0.84.

Harmony Biosciences (NASDAQ:HRMY) last posted its earnings results on Tuesday, November 4th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.05). The business had revenue of $239.46 million for the quarter, compared to analyst estimates of $222.68 million. Harmony Biosciences had a net margin of 22.50% and a return on equity of 24.88%. As a group, equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on HRMY. Wall Street Zen raised Harmony Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Harmony Biosciences in a report on Monday, December 29th. Mizuho boosted their price objective on shares of Harmony Biosciences from $39.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, December 1st. UBS Group cut their target price on Harmony Biosciences from $50.00 to $43.00 and set a “buy” rating on the stock in a research report on Wednesday, October 15th. Finally, Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $45.25.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial?stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.